Document:

Exhibit 10.1

 

EXECUTIVE EMPLOYMENT AGREEMENT

 

This Executive Employment
Agreement (this “Agreement”) is entered into as October 13, 2016 (the “Effective Date”),
between Moleculin Biotech, Inc., a Delaware corporation (the “Company”), and Walter V. Klemp (“Executive”).
The Company and Executive are sometimes hereinafter individually referred to as a “Party” and collectively
as the “Parties.”

 

WHEREAS, the Company
desires to employ Executive as its Chief Executive Officer and Executive desires to accept such employment;

 

WHEREAS, subject to
the terms of this Agreement, the Company may choose during the term of this Agreement to hire a new chief executive officer, and
upon such hire, and if requested by the Company, the Executive agrees to provide consulting services to the Company on an independent
contractor basis, pursuant to the Consulting Agreement in substantially the form set forth on Exhibit A (the
“Consulting Agreement”);

 

NOW, THEREFORE, in
consideration of the promises and mutual covenants contained herein and for other good and valuable consideration, the receipt
of which is mutually acknowledged, the Company and Executive agree as follows:

 

1.
          Term. This Agreement shall commence on the Effective Date and shall
remain in effect until terminated in accordance with Section 5 or Section 10 (the “Term”) (provided that
Section 4 shall continue in effect after Executive’s termination of employment).

 

2.
          Position and Duties.

 

(a)          During
the Term, Executive shall serve as the Company’s Chief Executive Officer. In such position, Executive shall (i) report to
the Board of Directors of the Company (the “Board”), (ii) perform such duties consistent with Executive’s
position as reasonably directed by the Board, and (iii) have the authority, responsibilities, and duties reasonably accorded to,
expected of, and consistent with Executive’s position.

 

(b)          Executive’s
principal place of employment shall be the principal offices of the Company currently located in Houston, Texas.

 

(c)          During
the Term, Executive shall devote Executive’s attention and efforts to the performance of Executive’s duties hereunder.
The foregoing limitations shall not be construed as prohibiting Executive from making personal investments in such form or manner
that will not require Executive’s services in the operation or affairs of the companies or businesses in which such investments
are made, violate the terms of this Agreement, or otherwise conflict or interfere with Executive’s responsibilities to the
Company.

 

     

     

    

 

3.
          Compensation and Benefits.

 

(a)          Executive’s
annual base salary (“Base Salary”) shall be $25,000 per month, payable bi-monthly on the Company’s
normal payroll dates; provided, however, that during the period commencing June 1, 2016 and ending June 1, 2017, $12,500 per month
of the Base Salary (the “Deferred Salary”) shall be deemed to be or actually deferred, as the case may
be, and shall be payable in a lump sum on the earlier of any termination of this Agreement, or June 1, 2019; provided further,
that if this Agreement is terminated pursuant to Section 10 because the Consultant Agreement takes effect, the Deferred Salary
shall be payable pursuant to the Consulting Agreement on the earlier of (i) the termination of Executive’s services (voluntarily
or involuntarily) pursuant to the Consulting Agreement or (ii) June 1, 2019. Executive’s Base Salary shall be reviewed annually
by the Board and the Board may, but shall not be required to, increase the Base Salary during the Term. However, Executive’s
Base Salary may not be decreased during the Term.

 

(b)          The
Company shall reimburse Executive for such business expenses as Executive shall from time to time incur on behalf of the Company
in accordance with the rules, guidelines, policies, and procedures of the Company and the Internal Revenue Service relating thereto.

 

4.
          Confidentiality; Restrictive Covenants.

 

(a)          Confidentiality.
Executive acknowledges that in the course of his employment for the Company, Executive will have access to certain confidential
information relating to the Company’s plans and strategies, including plans and strategies for research, development, production,
collaboration, or expansion, and other information about the Company’s business, which the Company desires to protect and
preserve in confidence (collectively referred to as “Confidential Information”). Executive agrees to
the following obligations with respect to the Confidential Information:

 

(i)          Executive
shall keep the Confidential Information in confidence, and shall not disclose or otherwise make available, or facilitate the availability
of the same or any part thereof to any person or entity, except as necessary in the course and scope of Executive’s duties
and responsibilities pursuant to this Agreement, as otherwise expressly permitted by the Company, or as required by law or legal
process.

 

(ii)         Executive
shall not make, disclose, or distribute, directly or indirectly, documents or copies of documents containing disclosures of the
Confidential Information, except as necessary in the course and scope of Executive’s duties and responsibilities pursuant
to this Agreement, or as required by law or legal process.

 

    2 

     

    

 

(iii)        Upon
termination of this Agreement, or otherwise upon request of the Company, Executive shall promptly return to the Company all of
the Confidential Information in his possession or control; provided, however, that Executive shall be permitted to retain a copy
of Confidential Information (subject to continuing confidentiality obligations with respect to such Confidential Information) as
necessary to render services pursuant to the Consulting Agreement, as subsequently agreed by the Parties, or as otherwise allowed
by law or legal process.

 

The provisions
of this Section 4(a) shall survive termination of this Agreement.

 

(b)          Non-Confidential
Information. The Company acknowledges and agrees that Executive’s obligations of confidence do not apply to, and
the term “Confidential Information” shall not include, any such information that (i) was already known to Executive
prior to becoming affiliated with the Company (or with Moleculin LLC) in any capacity, including as an officer, director, employee,
or consultant to the Company (or with Moleculin LLC), (ii) is publicly available or which becomes publicly available in the future
other than by breach of this Agreement by Executive, (iii) is disclosed to Executive by third parties under no obligation of confidence
to the Company, or (iv) is developed by Executive without reliance on the Confidential Information. In addition, Section 4(a) shall
not limit Executive’s performance of his services pursuant to (and in accordance with) the Consulting Agreement, if it takes
effect.

 

(c)          Non-Competition.
During the Term and for a period of 12 months thereafter, Executive shall not render any services, directly or indirectly, in any
capacity, to any person or entity, relating to developing or marketing any competitive products to those under development or being
marketed by the Company, within any state or foreign jurisdiction in which the Company or its affiliates is then developing, providing
or marketing its services or products (or engaged in active discussions to provide such services or products) except as expressly
permitted by the Company. Notwithstanding the foregoing, the Company acknowledges and agrees that Executive’s services pursuant
to the Consulting Agreement, or to Soliton, Inc. and any of its affiliates or collaborators, shall not in any way be limited by,
or be construed as a breach of, this Section 4(c).

 

Executive
agrees that in the event a court determines the length of time or the geographic area or activities prohibited under this Section
4(c) are too restrictive to be enforceable, the court shall reduce the scope of the restriction to the extent necessary to make
the restriction enforceable. In furtherance and not in limitation of the foregoing, the Company and Executive each intend that
the covenants contained in this Section 4(c) shall be deemed to be a series of separate covenants, one for each and every state,
territory or jurisdiction of the United States and any foreign country set forth therein.  If, in any judicial proceeding,
a court shall refuse to enforce any of such separate covenants, then such unenforceable covenants shall be deemed eliminated from
the provisions hereof for the purpose of such proceedings to the extent necessary to permit the remaining separate covenants to
be enforced in such proceedings.

 

    3 

     

    

 

(d)          Non-Solicitation.
During the Term and for a period of 12 months thereafter, Executive shall not solicit for employment or hire, or attempt to solicit
for employment or hire, any individual who is or was employed by the Company or any of its affiliates at any time within six months’
prior to the solicitation or hire (the “Restricted Personnel”); provided, however, that this restriction
shall not prohibit the solicitation for employment, or employment of, any such individual (i) whose employment was terminated by
the Company, (ii) who responds to a general solicitation through advertisements in social or other media of general circulation
advertising employment opportunities, to the extent that such advertisements are not aimed specifically at any Restricted Personnel,
(iii) who has been employed by Soliton, Inc. or its affiliates at any time, or (iv) pursuant to Consultant’s performance
of his services pursuant to the Consulting Agreement.

 

(e)          Assignment
of Inventions. Executive will promptly disclose to the Company any idea, invention, discovery or improvement, whether patentable
or not, related to the business of the Company (“Creations”), conceived or made by him alone or with
others at any time during his employment with the Company. Executive agrees that the Company owns all such Creations, conceived
or made by Executive alone or with others at any time during his employment with the Company, and Executive hereby assigns and
agrees to assign to the Company all rights he has or may acquire therein and agrees to execute any and all applications, assignments
and other instruments relating thereto which the Company deems necessary or desirable. These obligations shall continue beyond
the termination of his employment with the Company with respect to Creations and derivatives of such Creations conceived or made
during his employment with the Company. Executive understands that the obligation to assign Creations to the Company shall not
apply to any Creation which is developed entirely on his own time without using any of the Company’s equipment, supplies,
facilities, and/or Confidential Information unless such Creation (i) relates in any way to the business or to the current or anticipated
(as evidenced by written documentation) research or development of the Company or any of its affiliates; or (ii) results in any
way from his work at the Company.

 

Executive
agrees to cooperate reasonably with the Company, both during and after his employment with the Company, with respect to the procurement,
maintenance and enforcement of copyrights, patents, trademarks and other intellectual property rights (both in the United States
and foreign countries) relating to such Creations. Executive shall sign all papers, including, without limitation, copyright applications,
patent applications, declarations, oaths, formal assignments, assignments of priority rights and powers of attorney, which the
Company may deem necessary or desirable in order to protect its rights and interests in any Creations. Executive further agrees
that if the Company is unable, after reasonable effort, to secure Executive’s signature on any such papers, any officer of
the Company shall be entitled to execute such papers as his agent and attorney-in-fact, and Executive hereby irrevocably designates
and appoints each officer of the Company as his agent and attorney-in-fact to execute any such papers on his behalf and to take
any and all actions as the Company may deem necessary or desirable in order to protect its rights and interests in any Creations,
under the conditions described in this paragraph.

 

(f)          Injunctive
Relief. Without limiting the remedies available to the Company, Executive acknowledges that a breach of any of the covenants
contained in this Section 4 may result in material irreparable injury to the Company for which there is no adequate remedy at law,
that it will not be possible to measure precisely damages for such injuries and that, in the event of such a breach or threat thereof,
the Company shall be entitled, without the requirement to post bond or other security, to obtain a temporary restraining order
and/or injunction restraining Executive from engaging in activities prohibited by this Agreement or such other relief as may be
required to specifically enforce any of the covenants in this Section 4.

 

    4 

     

    

 

5.
          Termination.

 

(a)          Termination
For Cause. The Company may terminate this Agreement at any time for Cause (as defined below), in accordance with the terms
and conditions of this Agreement. “Cause” shall mean:

 

(i)          Executive’s
material and continued failure to use reasonable efforts to substantially perform his duties (as opposed to unsatisfactory performance
of duties) as the CEO of the Company;

 

(ii)         Executive’s
substantiated fraud or embezzlement against the Company;

 

(iii)        Executive’s
willful breach of Section 4; or

 

(iv)        Executive’s
conviction (or a plea of nolo contendere) for any felony under the laws of the United States or any State.

 

For purposes
of this provision, no act or failure to act on the part of Executive shall be considered “willful” unless it is done,
or omitted to be done, by Executive in bad faith or without reasonable belief that Executive’s action or omission was in
the best interests of the Company. Any act, or failure to act, based upon authority given pursuant to a resolution duly adopted
by the Board or upon the advice of counsel for the Company shall be conclusively presumed to be done, or omitted to be done, by
Executive in good faith and in the best interests of the Company. The Company shall give Executive written notice of any “Cause”
event, and Executive shall have 30 days from the delivery of such notice within which to cure any acts constituting Cause (if curable).

 

If terminated for “Cause,”
Executive shall be entitled to the following only (the benefits set forth in clauses (w), (x), (y), and (z) of this Section 5(a)
being, collectively, the “Accrued Rights”):

 

(w)          Executive’s
earned, but unpaid Base Salary (including any accrued but unpaid Deferred Salary) payable as of the date of termination, payable
in lump sum within seven days of Executive’s termination of employment;

 

(x)          Executive’s
earned but unpaid bonus or incentive compensation, if any, for the calendar year prior to the year in which Executive’s employment
terminates, payable at the same time it would have been paid had Executive not terminated;

 

    5 

     

    

 

(y)          reimbursement,
within 30 days following submission by Executive to the Company of appropriate supporting documentation, for any unreimbursed reasonable
business expenses incurred by Executive in the performance of Executive’s duties; and

 

(z)          such
other earned and accrued employee benefits, if any, as to which Executive may be entitled under the terms of the employee benefit
plans of the Company.

 

(b)          Voluntary
Termination by Executive. Executive may terminate his employment at any time without Good Reason (as defined in Section
5(d) below) upon 90 days’ prior written notice to the Company, in which event Executive shall be entitled to payment of the
Accrued Rights as described in Section 5(a).

 

(c)          Termination
Without Cause. The Company may terminate this Agreement and Executive’s employment, for any reason without Cause,
at any time upon 30 days’ prior written notice to Executive. Subject to the terms of Section 10, if this Agreement is terminated
without Cause, Executive shall be entitled to payment of the Accrued Rights as described in Section 5(a) and the following (the
benefits set forth in clauses (i) and (ii) of this Section 5(c) being, collectively, the “Severance Benefits”):

 

(i)          payment
of an amount equal to the greater of (A) Executive’s Base Salary for one year from
the date of termination of Executive’s employment, or (B) the Base Salary Executive would have received had he remained employed
through the third anniversary of the Effective Date; and

 

(ii)         payment
of a pro rata portion of Executive’s target bonus or incentive compensation, if any, for the calendar year in which Executive’s
employment terminates.

 

The Severance Benefits shall
be payable in lump sum within seven days of Executive’s termination.

 

(d)          By
Executive for Good Reason. Executive may terminate this Agreement for Good Reason, at any time in accordance with the following
terms and conditions. As used herein, “Good Reason” shall mean any of the following, without Executive’s
prior written consent:

 

(i)          a
material reduction in Executive’s title, authority, duties, or responsibilities;

 

(ii)         a
material reduction of Executive’s Base Salary;

 

(iii)        the
Company requires Executive to relocate to a facility or location more than 50 miles from the Company’s current headquarters
in Houston, Texas; or

 

(iv)        the
Company’s material breach of this Agreement.

 

    6 

     

    

 

Executive shall
give the Company written notice of any “Good Reason” event, and the Company shall have 30 days from the delivery of
such notice within which to cure any acts constituting Good Reason (if curable).

 

If Executive
resigns for Good Reason, Executive shall be entitled to (A) the Accrued Rights, payable as described in Section 5(a), and (B) the
Severance Benefits, payable as described in Section 5(c).

 

(e)          Death
or Disability of Executive. Executive’s employment shall terminate automatically upon Executive’s death. If
a Disability (as defined below) of Executive occurs, the Company may give to Executive written notice of its intention to terminate
Executive’s engagement. In such event, Executive’s engagement shall terminate effective on the 30th day after receipt
of such notice by Executive, provided that, within the 30 days after such receipt, Executive shall not have returned to full-time
performance of Executive’s duties. If this Agreement is terminated as a result of Executive’s death or Disability,
Executive shall be entitled to payment of the Accrued Rights as described in Section 5(a). Subject to applicable law, including
the Americans with Disabilities Act, as amended, the term “Disability” shall mean that Executive is,
by reason of any medically determinable physical or mental impairment (as determined by a physician reasonable acceptable to each
Party), unable to perform the essential functions of Executive’s job position with Company, with or without reasonable accommodation,
for six months – whether such six months be continuous or intermittent – within a 12-month period.

 

6.
          D&O Insurance. The Company shall purchase and maintain director
and officer liability insurance on such terms and providing such coverage as the Board determines is appropriate from time-to-time,
and Executive shall be covered by such insurance, pursuant to the terms of the applicable plan(s) and policy(ies), to the same
extent as similarly situated officers and directors of the Company.

 

7.
          Indemnification. The Company shall indemnify Executive in Executive’s
capacity as an officer or director of the Company and, if serving at the request of the Company as a director, manager, officer,
trustee, employee, agent, or similar functionary of another foreign or domestic limited liability company, corporation, trust,
partnership, joint venture, sole proprietorship, employee benefit plan, or other enterprise, in each of those capacities, against
any and all liability and reasonable expense that may be incurred by Executive in connection with or resulting from (a) any threatened,
pending, or completed action, suit, or proceeding, whether civil, criminal, administrative, arbitrative, or investigative (collectively,
a “Proceeding”), (b) an appeal in such a Proceeding, or (c) any inquiry or investigation that could lead
to such a Proceeding, all to the fullest extent permitted by applicable law; provided, however, that the Company shall not be obligated
to indemnify Executive to the extent any such liability or expense arises from or relates to Executive willful misconduct, embezzlement,
or fraud (“Excluded Misconduct”). The Company shall pay or reimburse, in advance of the final disposition
of the Proceeding, to Executive all reasonable expenses incurred by Executive to the extent Executive is or is threatened to be
made a named defendant or respondent in a Proceeding to the fullest extent permitted by applicable law; provided, however, that
the Company shall not be obligated to pay or reimburse Executive to the extent any liability or expense for which indemnification
is sought arises from or relates to Executive’s Excluded Misconduct. Any indemnification provided for in this Agreement shall
be in addition to all rights to which Executive may be entitled under any agreement or constituent document of the Company, or
as a matter of law or otherwise.

 

    7 

     

    

 

8.
          Section 409A.

 

(a)          Separation
from Service. Notwithstanding anything to the contrary in this Agreement, with respect to any amounts payable to Executive
under this Agreement in connection with a termination of Executive’s employment by the Company that would be considered “non-qualified
deferred compensation” under Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”),
in no event shall a termination of employment by the Company be considered to have occurred under this Agreement unless such termination
constitutes Executive’s “separation from service” with the Company as such term is defined in Treasury Regulation
Section 1.409A-1(h) and any successor provision thereto (“Separation from Service”).

 

(b)          Section
409A Compliance; Separate Payments. Notwithstanding anything contained in this Agreement to the contrary, to the maximum extent
permitted by applicable law, the amounts payable to Executive pursuant to Section 5 shall be made in reliance upon Treasury Regulation
Section 1.409A-1(b)(9)(iii) (relating to separation pay plans) or Treasury Regulation Section 1.409A-1(b)(4) (relating to short-term
deferrals), and each payment that Executive may be eligible to receive under this Agreement shall be treated as a separate and
distinct payment. However, to the extent any such payments are treated as “non-qualified deferred compensation” subject
to Section 409A of the Code, and if Executive is deemed at the time of his Separation from Service to be a “specified employee”
for purposes of Section 409A(a)(2)(B)(i) of the Code, then to the extent delayed commencement of any portion of the benefits to
which Executive is entitled under this Agreement is required in order to avoid a prohibited payment under Section 409A(a)(2)(B)(i)
of the Code, such portion of Executive’s termination benefits shall not be provided to Executive prior to the earlier of
(i) the expiration of the six-month period measured from the date of Executive’s Separation from Service, or (ii) the date
of Executive’s death. Upon the earlier of such dates, all payments deferred pursuant to the preceding sentence shall be paid
in a lump sum to Executive (or his personal representative), without interest. The determination of whether Executive is a “specified
employee” for purposes of Section 409A(a)(2)(B)(i) of the Code as of the time of his Separation from Service shall made by
the Company in accordance with the terms of Section 409A of the Code and applicable guidance thereunder (including Treasury Regulation
Section 1.409A-1(i) and any successor provision thereto).

 

(c)          Section
409A Interpretation. This Agreement is intended to be written, administered, interpreted, and construed in a manner such that
no payment or benefits provided under the Agreement become subject to (i) the gross income inclusion set forth within Section 409A(a)(1)(A)
of the Code, or (ii) the interest and additional tax set forth within Section 409A(a)(1)(B) of the Code (collectively, “Section
409A Penalties”), including, where appropriate, the construction of defined terms to have meanings that would not
cause the imposition of Section 409A Penalties.

 

    8 

     

    

 

(d)          Reimbursements
and In-kind Benefits. Any reimbursements by the Company to Executive of any eligible expenses under this Agreement that are
not excludable from Executive’s income for Federal income tax purposes (the “Taxable Reimbursements”)
shall be made by no later than the earlier of the date required pursuant to Section 3(b) and the last day of the taxable year of
Executive following the year in which the expense was incurred. The amount of any Taxable Reimbursements, and the value of any
in-kind benefits to be provided to Executive during any taxable year of Executive shall not affect the expenses eligible for reimbursement,
or in-kind benefits to be provided, in any other taxable year of Executive. The right to Taxable Reimbursement, or in-kind benefits
shall not be subject to liquidation or exchange for another benefit.

 

9.
          Successors.

 

(a)          This
Agreement is personal to Executive and without the prior written consent of the Company, Executive may not assign this Agreement
or delegate Executive’s duties hereunder. Any attempted assignment or delegation by Executive without the Company’s
prior written consent shall be void. This Agreement shall inure to the benefit of and be enforceable by Executive’s heirs,
estate, and legal representatives.

 

(b)          This
Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.

 

(c)          The
Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation, or otherwise) to all or substantially
all of the business and/or assets of the Company to assume expressly and agree to perform this Agreement in the same manner and
to the same extent that the Company would be required to perform it if no such succession had taken place. As used in this Agreement,
“Company” shall mean the Company as hereinbefore defined and any successor to its business and/or assets
as aforesaid which assumes and agrees to perform this Agreement by operation of law or otherwise.

 

10.         Consulting
Role. If during the Term, the Company determines to hire a new chief executive officer, the Company shall give Executive
at least 60 days’ advance notice of such event, and upon the later of the expiration of such 60-day notice period or the
commencement date of such replacement chief executive officer’s employment, this Agreement shall automatically terminate
and the Company shall have the right to retain Executive as a Consultant pursuant to the Consulting Agreement. If the Company notifies
the Executive that it intends to exercise its right pursuant to this section to retain Executive as a consultant, Executive shall
be entitled to the Accrued Rights as if he had resigned pursuant to Section 5(b), provided that (a) compliance with the notice
requirements is not required and (b) the Deferred Salary shall continue to be payable to Executive pursuant to the Consulting Agreement.
If for any reason the Company does not elect to retain Executive as a consultant pursuant to the Consulting Agreement, Executive
shall be entitled to the Accrued Rights and the Severance Benefits as if he had resigned with Good Reason pursuant to Section 5(d);
provided, that the time period for the Company to cure will be inapplicable.

 

    9 

     

    

 

11.         Miscellaneous.

 

(a)          This
Agreement shall be governed by and construed in accordance with the laws of the State of Texas, without reference to principles
of conflict of laws.

 

(b)          The
captions of this Agreement are not part of the provisions hereof and shall have no force or effect. The terms “including,”
“includes,” “include” and words of like import shall be construed broadly as if followed by the words “without
limitation.” The terms “herein,” “hereunder,” “hereof,” and words of like import refer
to this entire Agreement instead of just the provision in which they are found. The term “affiliate” means any person
or entity that directly or indirectly controls, is controlled by, or is under common control with the person or entity in question
(as used in this definition, the term “control” means the possession, directly or indirectly, of the power to direct
or cause the direction of the management and policies of a person or entity, whether through ownership of voting securities, by
contract or otherwise).

 

(c)          The
Company may withhold from any payment that it is required to make under this Agreement amounts sufficient to satisfy applicable
withholding requirements under any federal, state, or local law.

 

(d)          Any
notice required by this Agreement shall be given by email transmission confirmed by personal delivery (including delivery by reputable
messenger services such as Federal Express) or by prepaid, first class, certified mail, return receipt requested, addressed as
follows:

 

	If to Executive:	 	Walter V. Klemp
	 	 	1973 W. Clay St.
	 	 	Houston, TX 77019
	 	 	Email: wklemp@wkconsulting.net
	 	 	 
	If to the Company:	 	2575 West Bellfort, Suite 333
	 	 	Houston, Texas 77054
	 	 	Attention:  Chief Financial Officer
	 	 	Email:  jfoster@moleculin.com

 

or to such other address as either
Party shall have furnished to the other in writing in accordance herewith. Notice and communications shall be effective when actually
received by the addressee.

 

(e)          If
any provision of this Agreement is held to be illegal, invalid, or unenforceable under present or future laws effective during
the term of this Agreement, such provision shall be fully severable; this Agreement shall be construed and enforced as if such
illegal, invalid, or unenforceable provision had never comprised a portion of this Agreement; and the remaining provisions of this
Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid, or unenforceable provision or
by its severance from this Agreement. Furthermore, in lieu of such illegal, invalid, or unenforceable provision there shall be
added automatically as part of this Agreement a provision as similar in terms to such illegal, invalid, or unenforceable provision
as may be possible and be legal, valid, and enforceable.

 

    10 

     

    

 

(f)          The
failure by Executive or the Company to insist upon strict compliance with any provision of this Agreement or the failure to assert
any right Executive or the Company may have hereunder shall not be deemed to be a waiver of such provision or right or any other
provision or right of this Agreement.

 

(g)          The
provisions of this Agreement constitute the complete understanding and agreement between the Parties with respect to the subject
matter hereof, except for the provisions of applicable Company employee benefit plans and policies, insurance coverage,
and insurance benefits. Neither this Agreement nor any provision hereof may be amended, modified, or supplemented unless in writing,
executed by each Party. Except as otherwise expressly provided herein, no waiver with respect to this Agreement shall be enforceable
unless in writing and signed by the Party against whom enforcement is sought.

 

(h)          This
Agreement may be executed in counterparts, both of which when taken together shall be considered one and the same agreement and
shall become effective when counterparts have been signed by each Party and delivered to the other Party, it being understood that
both Parties need not sign the same counterpart. If any signature is delivered by facsimile transmission or by e-mail delivery
of a “.pdf” format data file, such signature shall create a valid and binding obligation of the Party executing (or
on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature
page were an original thereof.

 

[Signature Page Follows]

 

    11 

     

    

 

IN WITNESS WHEREOF,
the Parties have executed this Agreement to be effective as of the Effective Date.

 

	COMPANY:	 	EXECUTIVE:
	 	 	 
	Moleculin Biotech, Inc.	 	 
	 	 	 
	By:	/s/ Jacqueline Northcut	 	 
	Name:	Jacqueline Northcut	 	/s/ Walter V. Klemp
	Title:	Compensation Committee  - Chairperson	 	Walter V. Klemp

 

    12 

     

    

 

Exhibit A

 

Consulting Agreement

 

See attached.

 

    13 

     

    

 

CONSULTING AGREEMENT

 

This Consulting Agreement
(this “Agreement”) is entered into as of [___________], 2016 (the “Effective Date”),
between Moleculin Biotech, Inc., a Delaware corporation (the “Company”), and Walter V. Klemp (“Consultant”).
The Company and Consultant are sometimes hereinafter individually referred to as a “Party” and collectively
as the “Parties.”

 

WHEREAS, the Company
and Consultant were parties to that certain Executive Employment Agreement, dated as of __________, 2016, which was terminated
on [____________], 20[__] (the “Employment Agreement”); and

 

WHEREAS, subject to
the terms of this Agreement, the Company desires to engage Consultant as an independent contractor to perform the services set
forth on Exhibit A (the “Services”), and Consultant desires to accept such
engagement;

 

NOW, THEREFORE, in
consideration of the promises and mutual covenants contained herein and for other good and valuable consideration, the receipt
of which is mutually acknowledged, the Company and Consultant agree as follows:

 

1.           Term.
This Agreement shall commence on the Effective Date and shall remain in effect until ________, 2019 (the “Initial Term”).
After the Initial Term, this Agreement shall be automatically renewed for successive terms of one year each (a “Renewal
Period”), unless either Party gives notice that it does not intend to renew this Agreement not less than 90 days
prior to the end of any Term. For purposes of this Agreement, “Term” shall mean and include the Initial
Term and each Renewal Period. Notwithstanding the foregoing, Section 4 of the Agreement shall continue in effect after the termination
of this Agreement.

 

2.
          Services; Independent Contractor.

 

(a)          Subject
to the provisions of this Agreement, the Company hereby engages Consultant, and Consultant hereby accepts such engagement, as an
independent contractor to provide the Services. Consultant will perform the Services, during normal business hours, in a professional
and workmanlike manner. The Company acknowledges that Consultant provides services to other businesses, including as an officer
and director of Soliton, Inc., and that spending time doing so in a manner that does not prevent Consultant from performing the
Services shall not constitute a breach by Consultant of this Agreement. Consultant shall be entitled to suspend his performance
of the Services for an aggregate of four weeks during each year during the Term for vacation and other purposes. Consultant shall
not be in breach of this Agreement, nor shall the Company be excused from paying the Consulting Fee, if Consultant shall be unable
to perform the Services due to illness.

 

(b)          Consultant
is, and at all times during the Term shall be, an independent contractor of the Company, and this Agreement shall not be construed
to create any association, partnership, joint venture, employee, or agency relationship between Consultant and the Company for
any purpose. Consultant will not be entitled to participate in any benefits plans offered by the Company to its employees, except
for continuation coverage as provided by the Consolidated Omnibus Budget Reconciliation Act (COBRA), and the terms of any other
applicable post-employment employee benefit plans or insurance policies or coverages. The Company will not be responsible for withholding
or paying any income, payroll, Social Security, or other federal, state, or local taxes.

 

    14 

     

    

 

3.
          Consulting Fee; Expense Reimbursement.

 

(a)          In
consideration of Consultant providing the Services, the Company shall pay Consultant a monthly fee of $25,000 during the Term (the
“Consulting Fee”); provided, however, that until ________, 2017, $10,000 per month of the Consulting
Fee (the “Deferred Fee”), including any unpaid Deferred Salary (as defined in the Employment Agreement),
shall be deferred and shall be payable in lump sum on the earlier of the Consultant’s termination of Services to the Company
or ________, 2019. The Company shall pay to Consultant the Consulting Fee in arrears, in monthly installments on first day of each
month. The Consulting Fee shall be prorated for any partial calendar month. All payments shall be made in U.S. dollars.

 

(b)          The
Company shall reimburse Consultant for such business expenses as Consultant shall from time to time incur on behalf of the Company
in accordance with the rules, guidelines, policies, and procedures of the Company and the Internal Revenue Service relating thereto.

 

4.           Confidentiality;
Restrictive Covenants.

 

(a)          Confidentiality.
Consultant acknowledges that in the course of his Services, Consultant will have access
to certain confidential information relating to the Company’s plans and strategies, including plans and strategies for research,
development, production, collaboration, or expansion, and other information about the Company’s business, which the Company
desires to protect and preserve in confidence (collectively referred to as “Confidential Information”).
Consultant agrees to the following obligations with respect to the Confidential Information:

 

(i)          Consultant
shall keep the Confidential Information in confidence, and shall not disclose or otherwise make available, or facilitate the availability
of the same or any part thereof to any person or entity, except as necessary in the course and scope of Consultant’s duties
and responsibilities pursuant to this Agreement, as otherwise expressly permitted by the Company, or as required by law or legal
process.

 

(ii)         Consultant
shall not make, disclose, or distribute, directly or indirectly, documents or copies of documents containing disclosures of the
Confidential Information, except as necessary in the course and scope of Consultant’s duties and responsibilities pursuant
to this Agreement, or as required by law or legal process.

 

(iii)        Upon
termination of this Agreement, or otherwise upon request of the Company, Consultant shall promptly return to the Company all of
the Confidential Information in his possession or control; provided, however, that Consultant shall be permitted to retain a copy
of Confidential Information (subject to continuing confidentiality obligations with respect to such Confidential Information) as
subsequently agreed by the Parties, or as otherwise allowed by law or legal process.

 

    15 

     

    

 

The provisions
of this Section 4(a) shall survive termination of this Agreement.

 

(b)          Non-Confidential
Information. The Company acknowledges and agrees that Consultant’s obligations of confidence do not apply to, and
the term “Confidential Information” shall not include, any such information that (i) was already known to Consultant
prior to becoming affiliated with the Company (or with Moleculin LLC) in any capacity, including as an officer, director, employee,
or consultant to the Company (or with Moleculin LLC), (ii) is publicly available or which becomes publicly available in the future
other than by breach of this Agreement by Consultant, (iii) is disclosed to Consultant by third parties under no obligation of
confidence to the Company, or (iv) is developed by Consultant without reliance on the Confidential Information.

 

(c)          Non-Competition.
During the Term and for a period of 12 months thereafter, Consultant shall not render any services, directly or indirectly, in
any capacity, to any person or entity, relating to developing or marketing any competitive products to those under development
or being marketed by the Company, within any state or foreign jurisdiction in which the Company or its affiliates is then developing,
providing or marketing its services or products (or engaged in active discussions to provide such services or products) except
as expressly permitted by the Company. Notwithstanding the foregoing, the Company acknowledges and agrees that Consultant’s
services to Soliton, Inc. and any of its affiliates or collaborators, shall not in any way be limited by, or be construed as a
breach of, this Section 4(c).

 

Consultant
agrees that in the event a court determines the length of time or the geographic area or activities prohibited under this Section
4(c) are too restrictive to be enforceable, the court shall reduce the scope of the restriction to the extent necessary to make
the restriction enforceable. In furtherance and not in limitation of the foregoing, the Company and the Consultant each intend
that the covenants contained in this Section 4(c) shall be deemed to be a series of separate covenants, one for each and every
state, territory or jurisdiction of the United States and any foreign country set forth therein.  If, in any judicial proceeding,
a court shall refuse to enforce any of such separate covenants, then such unenforceable covenants shall be deemed eliminated from
the provisions hereof for the purpose of such proceedings to the extent necessary to permit the remaining separate covenants to
be enforced in such proceedings.

 

(d)          Non-Solicitation.
During the Term and for a period of 12 months thereafter, Consultant shall not solicit for employment or hire, or attempt to solicit
for employment or hire, any individual who is or was employed by the Company or any of its affiliates at any time within six months’
prior to the solicitation or hire (the “Restricted Personnel”); provided, however, that this restriction
shall not prohibit the solicitation for employment, or employment of, any such individual (i) whose employment was terminated by
the Company, (ii) who responds to a general solicitation through advertisements in social or other media of general circulation
advertising employment opportunities, to the extent that such advertisements are not aimed specifically at any Restricted Personnel,
or (iii) who has been employed by Soliton, Inc. or its affiliates at any time.

 

    16 

     

    

 

(e)          Assignment
of Inventions. Consultant will promptly disclose to the Company any idea, invention, discovery or improvement, whether
patentable or not, related to the business of the Company (“Creations”), conceived or made by him alone
or with others at any time during the Term. Consultant agrees that the Company owns all such Creations, conceived or made by Consultant
alone or with others at any time during the Term, and Executive hereby assigns and agrees to assign to the Company all rights he
has or may acquire therein and agrees to execute any and all applications, assignments and other instruments relating thereto which
the Company deems necessary or desirable. These obligations shall continue beyond the termination of his Service with respect to
Creations and derivatives of such Creations conceived or made during his Service with the Company. Consultant understands that
the obligation to assign Creations to the Company shall not apply to any Creation which is developed entirely on his own time without
using any of the Company’s equipment, supplies, facilities, and/or Confidential Information unless such Creation (i) relates
in any way to the business or to the current or anticipated (as evidenced by written documentation) research or development of
the Company or any of its affiliates; or (ii) results in any way from his work at the Company.

 

Consultant
agrees to cooperate reasonably with the Company, both during and after his Service with the Company, with respect to the procurement,
maintenance and enforcement of copyrights, patents, trademarks and other intellectual property rights (both in the United States
and foreign countries) relating to such Creations. Consultant shall sign all papers, including, without limitation, copyright applications,
patent applications, declarations, oaths, formal assignments, assignments of priority rights and powers of attorney, which the
Company may deem necessary or desirable in order to protect its rights and interests in any Creations. Consultant further agrees
that if the Company is unable, after reasonable effort, to secure Consultant’s signature on any such papers, any officer
of the Company shall be entitled to execute such papers as his agent and attorney-in-fact, and Consultant hereby irrevocably designates
and appoints each officer of the Company as his agent and attorney-in-fact to execute any such papers on his behalf and to take
any and all actions as the Company may deem necessary or desirable in order to protect its rights and interests in any Creations,
under the conditions described in this paragraph.

 

(f)          Injunctive
Relief. Without limiting the remedies available to the Company, Consultant acknowledges that a breach of any of the covenants
contained in this Section may result in material irreparable injury to the Company for which there is no adequate remedy at law,
that it will not be possible to measure precisely damages for such injuries and that, in the event of such a breach or threat thereof,
the Company shall be entitled, without the requirement to post bond or other security, to obtain a temporary restraining order
and/or injunction restraining Consultant from engaging in activities prohibited by this Agreement or such other relief as may be
required to specifically enforce any of the covenants in Section 4.

 

    17 

     

    

 

5.
          Termination.

 

(a)          Termination
For Cause. The Company may terminate this Agreement and Consultant’s Services at any time for Cause (as defined below),
in accordance with the terms and conditions of this Agreement. “Cause” shall mean:

 

(i)          Consultant’s
material and continued failure to perform the Services;

 

(ii)         Consultant’s
substantiated fraud or embezzlement against the Company;

 

(iii)        Consultant’s
willful breach of Section 4; or

 

(iv)        Consultant’s
conviction (or a plea of nolo contendere) for any felony under the laws of the United States or any State.

 

For purposes
of this provision, no act or failure to act on the part of Consultant shall be considered “willful” unless it is done,
or omitted to be done, by Consultant in bad faith or without reasonable belief that Consultant’s action or omission was in
the best interests of the Company. Any act, or failure to act, based upon authority given pursuant to a resolution duly adopted
by the Board or upon the advice of counsel for the Company shall be conclusively presumed to be done, or omitted to be done, by
Consultant in good faith and in the best interests of the Company. The Company shall give Consultant written notice of any “Cause”
event, and Consultant shall have 30 days from the delivery of written notice by the Company within which to cure any acts constituting
Cause (if curable).

 

If terminated for “Cause,”
Consultant shall be entitled to the following only (the benefits set forth in clauses (y) and (z) of this Section 5(a) being, collectively,
the “Accrued Rights”):

 

(y)          Consultant’s
earned but unpaid Consulting Fee (including any accrued but unpaid Deferred Fee), payable as of the date of termination, payable
in a lump sum within seven days of Consultant’s termination; and

 

(z)          reimbursement,
within 30 days following submission by Consultant to the Company of appropriate supporting documentation, for any unreimbursed
reasonable business expenses incurred by Consultant in the performance of the Services.

 

(b)          Voluntary
Termination by Consultant. Consultant may terminate this Agreement and Consultant’s Services at any time without
Good Reason (as defined in Section 5(d) below) upon 180 days’ prior written notice to the Company, in which event Consultant
shall be entitled to payment of the Accrued Rights as described in Section 5(a).

 

    18 

     

    

 

(c)          Termination
Without Cause. The Company may terminate this Agreement and Consultant’s Services, for any reason without Cause,
at any time upon 30 days’ prior written notice to Consultant. If this Agreement is terminated without Cause, Consultant shall
be entitled to payment of the Accrued Rights as described in Section 5(a) and payment of an amount equal to the greater of (A)
Consultant’s Consulting Fee for one year from the date of termination of this Agreement, or (B) the Consulting Fee Consultant
would have received had this Agreement remained in effect through ________, 2019 (the “Termination Benefit”).
For the avoidance of doubt, if this Agreement expires due to the Company’s failure to renew such Agreement pursuant to Section
1 above, such expiration or such failure by the Company to renew the Agreement shall not be deemed to be a termination without
Cause and Consultant shall not be entitled to any benefits other than the Accrued Rights.

 

The Termination Benefit shall
be payable in lump sum within seven days of Consultant’s termination.

 

(d)          By
Consultant for Good Reason. Consultant may terminate this Agreement and his Services for Good Reason, at any time, in accordance
with the following terms and conditions. As used herein, “Good Reason” shall mean any of the following,
without Consultant’s prior written consent:

 

(i)          the
Company requires Consultant to relocate to a facility or location more than 50 miles from the Company’s current headquarters
in Houston, Texas; or

 

(ii)         the
Company’s violation of any material provision of this Agreement, or any material provision of any other agreement entered
into between the Company and Consultant.

 

Consultant shall give the Company
written notice of any “Good Reason” event, and the Company shall have 30 days from the delivery of such notice within
which to cure any acts constituting Good Reason (if curable).

 

If Consultant
resigns for Good Reason, Consultant shall be entitled to (A) the Accrued Rights as described in Section 5(a), and (B) the Termination
Benefit as described in Section 5(c).

 

(e)          Death
or Disability of Consultant. This Agreement shall terminate automatically upon Consultant’s death. If a Disability
(as defined below) of Consultant occurs, the Company may give to Consultant written notice of its intention to terminate Consultant’s
engagement. In such event, Consultant’s engagement shall terminate effective on the 30th day after receipt of
such notice by Consultant, provided that, within the 30 days after such receipt, Consultant shall not have returned to full-time
performance of Consultant’s Services. If this Agreement is terminated as a result of Consultant’s death or Disability,
Consultant shall be entitled to payment of the Accrued Rights as described in Section 5(a). Subject to applicable law, the term
“Disability” shall mean that Consultant is, by reason of any medically determinable physical or mental
impairment (as determined by a physician reasonable acceptable to each Party), unable to perform the essential functions of Consultant’s
position with Company, with or without reasonable accommodation, for six months – whether such six months be continuous or
intermittent – within a 12-month period.

 

    19 

     

    

 

6.
          Indemnification. Each Party shall defend, indemnify, and hold the
other Party harmless from and against all losses, damages, liabilities, deficiencies, actions, judgments, interest, awards, penalties,
fines, costs, or expenses (including reasonable attorneys’ fees) arising out of or relating to such party’s intentional
breach of this Agreement. In addition, the Company shall defend, indemnify, and hold Consultant harmless from and against all losses,
damages, liabilities, deficiencies, actions, judgments, interest, awards, penalties, fines, costs, or expenses (including reasonable
attorneys’ fees) arising out of or relating to claims from other persons or entities made in connection with or as a result
of the performance by Consultant of the Services.

 

7.
          Successors.

 

(a)          This
Agreement is personal to Consultant and without the prior written consent of the Company, Consultant may not assign this Agreement
or delegate Consultant’s Services hereunder. Any attempted assignment or delegation by Consultant without the Company’s
prior written consent shall be void. This Agreement shall inure to the benefit of and be enforceable by Consultant’s heirs,
estate, and legal representatives.

 

(b)          This
Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.

 

(c)          The
Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation, or otherwise) to all or substantially
all of the business and/or assets of the Company to assume expressly and agree to perform this Agreement in the same manner and
to the same extent that the Company would be required to perform it if no such succession had taken place. As used in this Agreement,
“Company” shall mean the Company as hereinbefore defined and any successor to its business and/or assets
as aforesaid which assumes and agrees to perform this Agreement by operation of law or otherwise.

 

8.           Miscellaneous.

 

(a)          This
Agreement shall be governed by and construed in accordance with the laws of the State of Texas, without reference to principles
of conflict of laws.

 

(b)          The
captions of this Agreement are not part of the provisions hereof and shall have no force or effect. The terms “including,”
“includes,” “include” and words of like import shall be construed broadly as if followed by the words “without
limitation.” The terms “herein,” “hereunder,” “hereof,” and words of like import refer
to this entire Agreement instead of just the provision in which they are found. The term “affiliate” means any person
or entity that directly or indirectly controls, is controlled by, or is under common control with the person or entity in question
(as used in this definition, the term “control” means the possession, directly or indirectly, of the power to direct
or cause the direction of the management and policies of a person or entity, whether through ownership of voting securities, by
contract or otherwise).

 

    20 

     

    

 

(c)          Any notice
required by this Agreement shall be given by email transmission confirmed by personal delivery (including delivery by reputable
messenger services such as Federal Express) or by prepaid, first class, certified mail, return receipt requested, addressed as
follows:

 

	If to Consultant:	 	Walter V. Klemp
	 	 	1973 W. Clay St.
	 	 	Houston, TX 77019
	 	 	Email: wklemp@wkconsulting.net
	 	 	 
	If to the Company:	 	2575 West Bellfort, Suite 333
	 	 	Houston, Texas 77054
	 	 	Attention:  Chief Financial Officer
	 	 	Email: jfoster@moleculin.com

 

or to such other address as either
Party shall have furnished to the other in writing in accordance herewith. Notice and communications shall be effective when actually
received by the addressee.

 

(d)          If
any provision of this Agreement is held to be illegal, invalid, or unenforceable under present or future laws effective during
the term of this Agreement, such provision shall be fully severable; this Agreement shall be construed and enforced as if such
illegal, invalid, or unenforceable provision had never comprised a portion of this Agreement; and the remaining provisions of this
Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid, or unenforceable provision or
by its severance from this Agreement. Furthermore, in lieu of such illegal, invalid, or unenforceable provision there shall be
added automatically as part of this Agreement a provision as similar in terms to such illegal, invalid, or unenforceable provision
as may be possible and be legal, valid, and enforceable.

 

(e)          The
failure by Consultant or the Company to insist upon strict compliance with any provision of this Agreement or the failure to assert
any right Consultant or the Company may have hereunder shall not be deemed to be a waiver of such provision or right or any other
provision or right of this Agreement.

 

(f)          The
provisions of this Agreement constitute the complete understanding and agreement between the Parties with respect to the subject
matter hereof, except for the applicable post-employment benefit terms of the Parties’ Executive Employment Agreement,
and terms of any other applicable Company post-employment employee benefit plans, insurance policies or insurance coverages. Neither
this Agreement nor any provision hereof may be amended, modified, or supplemented unless in writing, executed by each Party. Except
as otherwise expressly provided herein, no waiver with respect to this Agreement shall be enforceable unless in writing and signed
by the Party against whom enforcement is sought.

 

(g)          This
Agreement may be executed in counterparts, both of which when taken together shall be considered one and the same agreement and
shall become effective when counterparts have been signed by each Party and delivered to the other Party, it being understood that
both Parties need not sign the same counterpart. If any signature is delivered by facsimile transmission or by e-mail delivery
of a “.pdf” format data file, such signature shall create a valid and binding obligation of the Party executing (or
on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature
page were an original thereof.

 

[Signature Page Follows]

 

    21 

     

    

 

IN WITNESS WHEREOF,
the Parties have executed this Agreement to be effective as of the Effective Date.

 

	COMPANY:	 	CONSULTANT:
	 	 	 
	Moleculin Biotech, Inc.	 	 
	 	 	 
	By:	          	 	 
	Name:	 	 	 
	Title:	 	 	Walter V. Klemp

 

     

     

    

 

Exhibit A

 

Services

 

Consultant will use his commercially reasonable
efforts to advise with respect to, and participate in, investor, banking and business development meetings involving the Company
from time to time, at reasonable times and locations designated by the Company (with reasonable advance written notice). It is
anticipated that such meetings are likely to involve national and international travel, including overnight stays (which travel
shall be reimbursable pursuant to Section 3(b)).

 

Consultant, upon reasonable notice, will
be available for teleconference, email and other electronic communications with the Company’s Board of Directors, CEO and
CFO on an as needed basis during regular business hours.Exhibit 10.2

 

CONFIDENTIAL
GENERAL RELEASE AND SEparation AGREEMENT

 

This Confidential General
Release and Separation Agreement (hereinafter “Agreement”), is entered into between Louis Ploth (“Employee”)
and Moleculin Biotech, Inc., a Delaware corporation (the “Company”).

 

WHEREAS, Employee’s
tenure as Chief Financial Officer of the Company ended on August 21, 2016, and Employee’s employment with the Company terminated
on August 31, 2016 (the “Termination Date”); and

 

WHEREAS, Employee and
the Company desire to enter into this Agreement in consideration for the severance payment and benefits set forth below.

 

NOW THEREFORE, in consideration
of the foregoing and of the promises and covenants contained herein, Employee and the Company agree as follows:

 

1.           Effective
as of August 19, 2016, Employee’s tenure as Chief Financial Officer of the Company was terminated. From the period from August
19, 2016 through his Termination Date, Employee continued as an employee of the Company and provided services to assist with the
transition of his responsibilities to the successor Chief Financial Officer.

 

2.           In
consideration for Employee entering into this Agreement, the Company will provide Employee with the following benefits:

 

		a.	The Company will pay Employee severance payments of $100,000 in the aggregate payable in equal
monthly installments, in the normal payroll payment manner over the 12 month period following the Termination Date, provided the
initial payment shall be on October 15, 2016, which payment shall provide for all payments due after the Termination Date and prior
to such date. Employee will not be expected to provide any additional services for such severance payments. In the event the Company
fails to make any of the payments required by this Section 2.a or by 2.c below by the time specified in this Agreement, after receipt
by the Company from Employee of written notice of such failure and after the expiration of a five-day cure period with respect
to such failure, all of Employee’s obligations under this Agreement shall immediately terminate, and all releases and waivers
provided by Employee under this Agreement, including but not limited to those under Section 3, shall be deemed terminated and void
ab initio.

 

		b.	Employee will become vested in 50,000 shares of the Stock Option granted to him on December 10,
2015 under the Company’s 2015 Stock Plan, and he will have until May 31, 2020 in which to exercise such vested portion in
accordance with the terms of the Plan and related award agreement. This Agreement shall serve as an amendment to the Non-Qualified
Stock Option Agreement dated December 10, 2015 with Louis Ploth. The Company will use its commercially reasonable efforts to assist
Employee in transferring shares of the Company’s common stock he receives from the exercise of such Stock Option by, among
other things, promptly communicating with its transfer agent and by using its commercially reasonable efforts to have any instruction
letter or legal opinion required by the transfer agent for the transfer of such shares to be delivered to the transfer agent in
a prompt manner, to the extent permitted by law and in accordance with any lock-up agreement entered into by Employee.

 

     

     

    

 

		c.	The Termination Date shall be considered a “qualifying event” as such term is defined
in Title I, Part 6 of the Employee Retirement Income Security Act of 1974 (“COBRA”), and any continued coverage by
Employee, his spouse or eligible dependents under the Company’s group health plan after the Termination Date shall be considered
COBRA coverage. For the eleven months beginning October 1, 2016, the Company shall either pay Employee $1,496.99 per month (regardless
of whether Employee elects COBRA coverage) or his COBRA payment on his behalf.

 

		d.	Employee acknowledges that he is not otherwise entitled to the benefits described above, and that
such benefits are available to Employee only if Employee executes and does not revoke this Agreement. Payments of severance described
in 2(a) above will begin on the first payroll following the expiration of the revocation period described in Section 7 of this
Agreement, and any payment that would have been made prior to such expiration date will be included in the first payment made to
Employee. The Stock Option vesting described in 2(b) above will occur on the first day following the expiration of the revocation
period described in Section 7 of this Agreement.

 

3.           In
consideration of the agreement of the Company to provide Employee with the severance pay and other consideration as set forth in
this Agreement:

 

		a.	Employee, individually and on behalf of his heirs, legal representatives and assigns, does hereby
release and forever discharge the Company and the Released Parties (as defined in Section 1(b)) with respect to any waivable claim,
damage, cost, debt, demand, suit, cause of action and liability of any kind or nature whatsoever, including but not limited to
attorneys’ fees, whether known or unknown, fixed or contingent, that Employee ever had or may now or hereafter have or claim
to have or incur as a result of any matter whatsoever, including but not limited to any and all claims which he, or anyone acting
through him or on his behalf, may have relating to his employment or cessation of employment with the Company, whether now known
or later discovered.

 

		b.	The Released Parties include: (i) the Company (ii) all current and former Company parents, subsidiaries,
related companies, affiliates, partnerships or joint ventures, and (iii) with respect to each entity set forth in (i) and (ii)
above, their predecessors, successors, current and former employees, officers, directors, managers, owners, representatives, assigns,
attorneys, agents, insurers, employee benefit programs (and the trustees, administrators, and fiduciaries of such programs).

 

    2 

     

    

 

		c.	This general release includes but is not limited to claims arising out of or in connection with
(i) Employee’s employment relationship with the Released Parties; (ii) any allegation that one or more of the Released Parties
wrongfully or unlawfully terminated Employee’s employment or discharged Employee; (iii) any allegation of violation of Title
VII of the Civil Rights Act of 1964, the Employee Retirement Income Security Act of 1974, the Age Discrimination in Employment
Act, the Older Workers Benefit Protection Act of 1990, the Americans with Disabilities Act of 1990, the Family and Medical Leave
Act of 1993, the National Labor Relations Act, the Worker’s Adjustment and Retraining Notification Act; (iv) any allegation
of defamation, intentional or negligent infliction of emotional distress, workplace harassment or discrimination, retaliation,
whistleblowing, invasion of privacy, violation of public policy, negligence or any other tort; (v) any allegation of a breach of
any contract of employment, express or implied, or of a violation of any Company policy or procedure, of the provisions of the
Constitution of the United States or the constitution of any state, or of any other law, rule, regulation or ordinance pertaining
to employment; and/or the termination of employment; and/or (vi) any other statutory or common law cause of action.

 

		d.	Nothing in this Agreement shall be interpreted as interfering with the right to file, assist or
participate in a claim that cannot be waived. Further, nothing shall be interpreted as interfering with the right to file, assist
or participate in a charge with the Equal Employment Opportunity Commission, or other administrative agency with jurisdiction;
however, even if Employee has such a right, Employee agrees that he shall not obtain, and hereby waives his right to, any monetary
or other individual relief for any claim or liability released in this Agreement.

 

		e.	Nothing contained herein shall purport to waive or otherwise affect any of Employee’s rights
or claims that may arise after Employee signs this Agreement.

 

		f.	Employee affirms that after his receipt of the salary he has earned through the Termination Date,
Employee will have received all compensation to which he may be entitled, except as set forth in Section 2 above. Employee represents
that he is not aware of any facts on which a claim under the Fair Labor Standards Act or under applicable state minimum wage or
wage payment laws could be brought.

 

4.           Employee
acknowledges and understands that he waives any right or claim to reinstatement to any position with the Company or the Released
Parties and agrees that he will not seek or apply for employment with the Company or the Released Parties as an employee, contractor,
consultant or in any other capacity.

 

5.           It
is understood that this Agreement does not constitute an admission of liability on the part of the Company or the Released Parties
by whom any liability is expressly denied, but is made to terminate any controversy or potential controversy with respect to Employee’s
employment and the cessation of Employee’s employment with the Company.

 

    3 

     

    

 

6.           Each
of Employee and Company agrees, and the Company agrees to cause its officers to agree, that he, it or they will not make, or cause
to be made, any disparaging, negative or adverse statements whatsoever, whether in public or private, and whether written, oral,
on social media or otherwise, concerning any of the Released Parties or the Employee.

 

7.           Employee
understands that he has the right under the Age Discrimination in Employment Act and the Older Workers Benefit Protection Act to
consider this Agreement for a period of 21 days. If Employee decides to sign this Agreement prior to the end of the 21 day period,
he does so knowingly and voluntarily and without inducement by the Released Parties, or any agent or employee of any of the Released
Parties, through fraud, coercion, misrepresentation or a threat to withdraw or alter the Released Parties’ offer, prior to
the expiration of the 21 day time period.

 

8.           Employee
understands that this Agreement is revocable by Employee for seven calendar days following Employee’s signing of this Agreement,
and that this Agreement shall not become effective or enforceable until that revocation period has expired. Employee understands
that to revoke this Agreement he must send a signed written revocation within seven days of signing this Agreement. Employee understands
and agrees that this Agreement shall automatically become enforceable and effective on the eighth day after Employee signs it so
long as Employee has not revoked Employee’s signature in the manner prescribed herein. Should Employee exercise Employee’s
right to revoke Employee’s signature within the seven day period following the signing of this Agreement, Employee understands
and agrees that this Agreement is null and void and Employee will not receive the severance payments or benefits set forth in Section
2.

 

The signed Agreement
and any revocation thereof must be sent via certified mail or overnight delivery to:

 

Walter Klemp, Acting Chief Executive Officer 

2575 West Belfort, Suite 333 

Houston, TX 77054

 

with a copy
to:

 

Cavas S. Pavri 

Schiff Hardin LLP 

100 N. 18th Street, Suite 300 

Philadelphia, PA 19103

 

Employee agrees
to keep the fact, terms and conditions of this Agreement completely confidential, and that, except as required by law, Employee
shall not disclose any information concerning this Agreement to anyone other than Employee’s lawyer, spouse, and tax advisor(s),
who will be informed of and bound by this confidentiality clause.

 

9.           The
terms of this Agreement are contractual and not a mere recital and cannot be changed except by written agreement of the parties.

 

    4 

     

    

 

10.         This
Agreement represents the entire agreement of the parties and supersedes any previous understandings or agreements, oral or written,
except that Employee understands and agrees that this Agreement does not supersede any confidentiality, noncompete or nonsolicit
agreements or obligations Employee may be subject to relating to the Company.

 

11.         This
Agreement, and each and every term and provision hereof, shall be construed in accordance with the laws of the State of Texas.
If any provision of this Agreement shall for any reason be held invalid or unenforceable, such invalidity or unenforceability shall
not affect any other provision hereof, but this Agreement shall, in such event, be construed as if such invalid and/or unenforceable
provision had never been contained herein.

 

12.         Employee
acknowledges that Employee has carefully and fully read this Agreement prior to signing it. Employee also acknowledges that Employee
has been advised by the Company to consult with an attorney of Employee’s choice, and at Employee’s expense, prior
to signing this Agreement and has signed this Agreement knowingly, voluntarily and freely, and with such counsel as Employee deems
appropriate.

 

[Remainder of page intentionally left
blank.]

 

    5 

     

    

 

THIS AGREEMENT INCLUDES A WAIVER AND
RELEASE — READ BEFORE SIGNING

 

You are advised
to consult with an attorney prior to signing this Agreement. You have a period of 21 days in which to consider this Agreement.
The 21-day period starts on October 5, 2016. If you do not sign and return this Agreement to the Company within this 21-day period,
you will not receive any severance benefits described in Paragraph 2 of this Agreement. Following your execution of the Agreement,
you will have a 7-day period in which to revoke your acceptance of this Agreement by giving written notice to the Company. If you
choose not to revoke, this Agreement will then become effective and enforceable on the 8th day following the date you execute and
deliver this Agreement.

 

	EMPLOYEE	 	MOLECULIN BIOTECH, INC.
	 	 	 
	/s/ Louis Ploth	 	By:	/s/ Walter Klemp
	Name:	Louis Ploth Jr.	 	Its:	CEO
	 	 	 	 	 
	Dated:	10/7/16	 	Dated:	10/8/16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}]]